OTHER INCOME (NET)

9 Months Ended

Sep. 30, 2018

Other Nonoperating Income (Expense) [Abstract]

Other (Income)/Expense [Text Block]

OTHER INCOME (NET)

	Three Months Ended September 30,						Nine Months Ended September 30,
Dollars in Millions	2018			2017			2018			2017
Interest expense	$	44		$	48		$	135		$	145
Investment income	(44		)	(32		)	(118		)	(87		)
Loss/(gain) on equity investments	(97		)	(5		)	244			(17		)
Provision for restructuring	45			28			102			207
Litigation and other settlements	11			—			10			(489		)
Equity in net income of affiliates	(22		)	(21		)	(73		)	(59		)
Divestiture (gains)/losses	(108		)	1			(178		)	(126		)
Royalties and licensing income	(338		)	(209		)	(1,058		)	(1,093		)
Transition and other service fees	—			(12		)	(5		)	(32		)
Pension and postretirement	(10		)	(19		)	(40		)	(29		)
Intangible asset impairment	—			—			64			—
Loss on debt redemption	—			—			—			109
Other	11			(11		)	5			(26		)
Other income (net)	$	(508	)	$	(232	)	$	(912	)	$	(1,497	)

• Loss/(gain) on equity investments includes a $100 million increase and $307 million decrease in fair value adjustments for the equity investment in Nektar in the three and nine months ended September 30, 2018, respectively.

• Litigation and other settlements includes BMS's share of a patent-infringement litigation settlement of $481 million related to Merck's PD-1 antibody Keytruda* in the first quarter of 2017.

• Royalties and licensing income includes up-front licensing fees of $470 million from Biogen and Roche in the second quarter of 2017.